Evident Technologies Announces Issuance of Key Patent for Semiconductor Nanocrystals Made From III V Materials: related news

Evident Technologies Announces Issuance of Key Patent for Semiconductor Nanocrystals Made From III-V Materials

Evident Technologies, Inc. today announced the issuance of US Patent No. 7,399,429 covering the ability to make semiconductor nanocrystals from III-V materials, including indium galium phosphide. This newly issued patent represents a dramatic increase in the advancement of semiconductor materials science and augments the breadth of the company's intellectual property portfolio.

Evident Technologies Announces Issuance of Key Patent for Semiconductor Nanocrystals Made From III-V Materials

Evident Technologies Announces Issuance of Key Patent for Semiconductor Nanocrystals Made From III-V Materials

Evident Technologies Announces Issuance of Key Patent for Semiconductor Nanocrystals Made From III-V Materials

Evident Technologies Announces Issuance of Key Patent for Semiconductor Nanocrystals Made From III-V Materials

Evident Technologies Announces Issuance of Key Patent for Semiconductor Nanocrystals Made From III-V Materials

NEW YORK - (Business Wire) Evident Technologies, Inc. today announced the issuance of US Patent No. 7,399,429 covering the ability to make semiconductor nanocrystals from III-V materials, including indium galium phosphide. This newly issued patent represents a dramatic increase in the advancement of semiconductor materials science and augments the breadth of the company

CSMG Technologies Announces Key Fifth U.S. Tissue Bonding/Welding Patent Approved

a technology management company, announced the company has received approval of its fifth U.S. patent. The approval is on a key divisional application for "Bonding of Soft Biological Tissues by Passing High Frequency Electric Current Therethrough" for CSMG Technologies subsidiary Live Tissue Connects ("LTC") platform tissue bonding/welding technology. The patent approval follows the issuance of four other U.S. patents, a European Union patent, in eight European countries, Ukraine, Canada and Australia with 14 U.S. and international patents pending. Donald S. Robbins, President and CEO of CSMG Technologies, said, "This key U.S. patent approval re-enforces our patent portfolio and expands LTC's commercial possibilities while increasing our shareholder value.

Evident Technologies Reveives Key Patent for Semiconductor Nanocrystals Made From III-V Materials

New Collaboration to Provide Innovative Parametric Yield Optimization to the Sub-90nm Analog Designers' Community

CSMG Technologies Announces Key Fifth U.S. Tissue Bonding/Welding Patent Approved

PRNewswire-FirstCall/ -- CSMG Technologies, Inc., (CTGI), a technology management company, announced the company has received approval of its fifth U.S. patent. The approval is on a key divisional application for "Bonding of Soft Biological Tissues by Passing High Frequency Electric Current Therethrough" for CSMG Technologies subsidiary Live Tissue Connects ("LTC") platform tissue bonding/welding technology. The patent approval follows the issuance of four other U.S. patents, a European Union patent, in eight European countries,

CSMG Technologies Announces Key Fifth U.S. Tissue Bonding/Welding Patent Approved

PRNewswire-FirstCall/ -- CSMG Technologies, Inc., (OTC Bulletin Board: CTGI), a technology management company, announced the company has received approval of its fifth U.S. patent. The approval is on a key divisional application for "Bonding of Soft Biological Tissues by Passing High Frequency Electric Current Therethrough" for CSMG Technologies subsidiary Live Tissue Connects ("LTC") platform tissue bonding/welding technology. The patent approval follows the issuance of four other U.S. patents, a European Union patent, in eight European countries,

CSMG Technologies Announces Key Fifth U.S. Tissue Bonding/Welding Patent Approved

CORPUS CHRISTI, Texas, Oct. 10 /PRNewswire-FirstCall/ -- CSMG Technologies, Inc., , a technology management company, announced the company has received approval of its fifth U.S. patent. The approval is on a key divisional application for "Bonding of Soft Biological Tissues by Passing High Frequency Electric Current Therethrough" for CSMG Technologies subsidiary Live Tissue Connects ("LTC") platform tissue bonding/welding technology. The patent approval follows the issuance of four other U.S. patents, a European Union patent, in eight European countries, Ukraine, Canada and Australia with 14 U.S. and international patents pending.

CSMG Technologies Announces Key Fifth U.S. Tissue Bonding/Welding Patent Approved

CORPUS CHRISTI, Texas, Oct. 10 /PRNewswire-FirstCall/ -- CSMG Technologies, Inc., (OTC Bulletin Board: CTGI - News), a technology management company, announced the company has received approval of its fifth U.S. patent. The approval is on a key divisional application for "Bonding of Soft Biological Tissues by Passing High Frequency Electric Current Therethrough" for CSMG Technologies subsidiary Live Tissue Connects ("LTC") platform tissue bonding/welding technology. The patent approval follows the issuance of four other U.S. patents, a European Union patent, in eight European countries, Ukraine, Canada and Australia with 14 U.S. and international patents pending.

Salix Announces Issuance of U.S. Patent for Rifaximin

RALEIGH, N.C. - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 7,452,857. This patent provides protection until August 2019. U.S. Patent No. 7,452,857 provides protection relating to rifa

Court Stays Patent Infringement Suit Brought against Candela byPalomar

Candela Corporation (NASDAQ: CLZR) announced today that the United States District Court for the District of Massachusetts agreed to stay the patent litigation that Palomar Medical Technologies, Inc. (�Palomar�) brought against the Company in August 2006. In that suit, Palomar asserts that the Company infringed upon U.S. Patent No. 5,735,844 (the ‘ “844 Patent�) and U.S. Patent No. 5,595,568, which is related to the ‘844 Patent (the ‘ “568 Patent�).

Court Stays Patent Infringement Suit Brought against Candela by Palomar

Candela Corporation (NASDAQ: CLZR) announced today that the United States District Court for the District of Massachusetts agreed to stay the patent litigation that Palomar Medical Technologies, Inc. (�Palomar�) brought against the Company in August 2006. In that suit, Palomar asserts that the Company infringed upon U.S. Patent No. 5,735,844 (the ‘ “844 Patent�) and U.S. Patent No. 5,595,568, which is related to the ‘844 Patent (the ‘ “568 Patent�).

Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908

PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced the issuance of U.S. Patent No. 7,429,664, which provides composition of matter patent protection for a series of nicotinic alpha-7 receptor agonists. These include R3487/MEM 3454 and R4996/MEM 63908, which are both being developed in partnership with Roche for the treatment of cognitive disorders such as Alzheimer's disease and cognitive impairment associated with schizophrenia (CIAS). The term of the patent extends until at least 2025, which does not reflect any potential patent term extensions.

Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908

MONTVALE, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. today announced the issuance of U.S. Patent No. 7,429,664, which provides composition of matter patent protection for a series of nicotinic alpha-7 receptor agonists. These include R3487/MEM 3454 and R4996/MEM 63908, which are both being developed in partnership with Roche for the treatment of cognitive disorders such as Alzheimer's disease and cognitive impairment associated with schizophrenia (CIAS). The term of the patent extends until at least 2025, which does not reflect any potential patent term extensions.

Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908

MONTVALE, N.J., October 27, 2008 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. today announced the issuance of U.S. Patent No. 7,429,664, which provides composition of matter patent protection for a series of nicotinic alpha-7 receptor agonists. These include R3487/MEM 3454 and R4996/MEM 63908, which are both being developed in partnership with Roche for the treatment of cognitive disorders such as Alzheimer's disease and cognitive impairment associated with schizophrenia (CIAS). The term of the patent extends until at least 2025, which does not reflect any potential patent term extensions.

Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908

MONTVALE, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced the issuance of U.S. Patent No. 7,429,664, which provides composition of matter patent protection for a series of nicotinic alpha-7 receptor agonists. These include R3487/MEM 3454 and R4996/MEM 63908, which are both being developed in partnership with Roche for the treatment of cognitive disorders such as Alzheimer's disease and cognitive impairment associated with schizophrenia (CIAS). The term of the patent extends until at least 2025, which does not reflect any potential patent term extensions.

Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908

MONTVALE, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY - News) today announced the issuance of U.S. Patent No. 7,429,664, which provides composition of matter patent protection for a series of nicotinic alpha-7 receptor agonists. These include R3487/MEM 3454 and R4996/MEM 63908, which are both being developed in partnership with Roche for the treatment of cognitive disorders such as Alzheimer's disease and cognitive impairment associated with schizophrenia (CIAS). The term of the patent extends until at least 2025, which does not reflect any potential patent term extensions.

Halliburton Tries To Patent Form Of Patent Trolling

We see all sorts of ridiculous patent applications and patents, but my favorites tend to be the patents that have to do with patents themselves (such as the patent app on a method for filing a patent). However, the folks over at Patently-O have highlighted a fascinating patent application from an attorney at Halliburton, which appears to be an attempt to patent the process of patent trolling. The application covers, quite explicitly, having a company (we'll say Company A) that does not invent something, find a company (Company B) that did invent something, but chose to use trade secret protection, rather than patents. Then, the Company A files a patent covering Company B's technology, and then use the issued patent to get money out of Company B.

Halliburton Applies For Patent-Trolling Patent

An anonymous reader writes "Halliburton, the company many folks know as Dick Cheney's previous employer, has apparently taken an interest in methods of patent trolling. In fact, according to Techdirt, the company has applied for a patent on patent trolling. Specifically, it's applied for a patent on the process of finding a company that protected an invention via trade secret, figuring out what that secret is, patenting it ... and then suing the original company. Hopefully, the patent office rejects this patent, because I somehow doubt that Halliburton is trying to get the patent as a way to block others from patent trolling."

Calypso Wireless, Inc. Announces Patent Issuance in 26th and 27th European Country for Its ASNAP(TM) Technology

Calypso Wireless, Inc. Announces Patent Issuance in 26th and 27th European Country for Its ASNAP(TM) Technology

Salix Announces Issuance of U.S. Patent for Rifaximin

Salix Pharmaceuticals, Ltd. (SLXP) today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 7,452,857. This patent provides protection until August 2019.

X1 Gains Patent

Pasadena-based X1 Technologies, which develops enterprise search software, said Monday that it has received a patent for technology in its products. According to the firm, it received U.S Patent 7,424,510, entitled "Methods and Systems for Web Based Incremental Searches," covering its method of displaying search results. The patent names Idealab's Bill Gross and Steven Lee Colwell as inventors, and was originally filed by the firm in September of 2003. The patent is behind X1's incremental search technology, which refines searches as a user types in each character of their search. The patent filing was made for X1 Technologies by Knobbe Martens Olson & Bear, LLP. X1 Technologies develops enterprise search software for finding documents, emails, and other related information.

Revolutions Medical Patent News

Revolutions Medical Corporation (OTCBB: RMCP – News) is pleased to report that it has recently received a notice of allowance through its patent attorney Richard Moseley from the United States Patent and Trademark Office for issuance as a patent for its Rev Vac Safety syringe. This patent will be issued shortly and will be the second US patent protecting its proprietary Rev Vac Safety Syringe. Ron Wheet, CEO of Revolutions Medical states "the timing couldn't be any better. As we await clearance from the FDA on our pre-market 510k application for our Rev Vac Safety Syringe, we now will have two strong US patents protecting our proprietary technology. In addition, we have also spent the time and money necessary to protect our US patents internationally over the last 6 months.

Leader Sues Facebook for Patent Infringement

COLUMBUS, Ohio, Nov. 19 /PRNewswire/ -- Leader Technologies Incorporated of Columbus, Ohio, announced today that it has filed a patent infringement lawsuit against Facebook, Inc. of Palo Alto, California. (Logo: http://www.newscom.com/cgi-bin/prnh/20081119/CLW100LOGO ) The complaint was filed in the United States District Court for the District of Delaware and alleges that Facebook infringes Leader's U.S. Patent No. 7,139,761 issued by the United States Patent and Trademark Office on November 21, 2006. The '761 Patent generally relates to a method and system for the management and storage of electronic information. Leader seeks damages and an injunction against Facebook for its willful infringement of the '761 Patent. Leader was founded by Michael McKibben in 1997 and is a pioneer in web-based collaboration platforms.

Search took 3.06 seconds.